Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2001 1
2004 1
2005 3
2007 3
2008 4
2009 1
2010 5
2011 1
2012 1
2013 1
2018 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
In a dosing range at less than 1 mug per day, oral naltrexone or intravenous naloxone potentiate opioid analgesia by acting on filamin A, a scaffolding protein involved in mu-opioid receptor signaling. This dose is termed ultra low-dose naltrexone/nalo …
In a dosing range at less than 1 mug per day, oral naltrexone or intravenous naloxone potentiate opioid analgesia by acting on filamin A, a …
Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.
Webster LR. Webster LR. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. doi: 10.1517/13543784.16.8.1277. Expert Opin Investig Drugs. 2007. PMID: 17685875 Review.
To evaluate the safety and efficacy of the oxycodone/naltrexone combination, three clinical studies have been conducted, one in healthy volunteers and the other two in patients with chronic pain. The putative mechanism of ultra-low-dose naltrexone is t …
To evaluate the safety and efficacy of the oxycodone/naltrexone combination, three clinical studies have been conducted, one in healthy volu …
Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.
Mattioli TA, Milne B, Cahill CM. Mattioli TA, et al. Mol Pain. 2010 Apr 16;6:22. doi: 10.1186/1744-8069-6-22. Mol Pain. 2010. PMID: 20398374 Free PMC article.
Astrocyte and microglial immuno-labelling was attenuated in rats co-administered ultra-low dose naltrexone compared to morphine-treated rats and did not differ from controls. ...CONCLUSION: Taken together, we demonstrate a positive correlation between …
Astrocyte and microglial immuno-labelling was attenuated in rats co-administered ultra-low dose naltrexone compa …
Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. Largent-Milnes TM, et al. J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12. J Pain. 2008. PMID: 18468954 Free PMC article.
Repeated administration of oxycodone alone or in combination with ultra-low-dose naltrexone (NTX) was assessed on the SNL-induced MOR-G(s) coupling as well as on neuropathic pain behavior. ...
Repeated administration of oxycodone alone or in combination with ultra-low-dose naltrexone (NTX) was assessed o …
Ultra-low dose naltrexone enhances cannabinoid-induced antinociception.
Paquette J, Olmstead MC. Paquette J, et al. Behav Pharmacol. 2005 Dec;16(8):597-603. doi: 10.1097/00008877-200512000-00001. Behav Pharmacol. 2005. PMID: 16286810
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influences cannabinoid-induced antinociception. ...Tail-flick latencies were recorded for 3 h, at 10-min intervals for the first hour, and at 15- …
As opioid and cannabinoid systems interact, this study investigated whether ultra-low dose naltrexone also influ …
Antinociceptive effect of ultra-low dose naltrexone in a pre-clinical model of postoperative orofacial pain.
Hummig W, Baggio DF, Lopes RV, Dos Santos SMD, Ferreira LEN, Chichorro JG. Hummig W, et al. Brain Res. 2023 Jan 1;1798:148154. doi: 10.1016/j.brainres.2022.148154. Epub 2022 Nov 4. Brain Res. 2023. PMID: 36335995 Free article.
Naltrexone (NTX) is a non-selective opioid receptor antagonist that has been shown to modulate neuro-inflammation when employed in low to ultra-low doses. In addition, ultra-low dose naltrexone (ULDN) has been shown to potentiate opioids' analgesia and …
Naltrexone (NTX) is a non-selective opioid receptor antagonist that has been shown to modulate neuro-inflammation when employed in low to ul …
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
Olmstead MC, Burns LH. Olmstead MC, et al. Psychopharmacology (Berl). 2005 Sep;181(3):576-81. doi: 10.1007/s00213-005-0022-7. Epub 2005 Oct 12. Psychopharmacology (Berl). 2005. PMID: 16010543
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVES: To determine whether ultra-low-dose naltrexone (NTX) coadministration alters the rewarding effects of opiates or the aversive effe …
RATIONALE: Ultra-low-dose opioid antagonists enhance opiate analgesia and attenuate tolerance and withdrawal. OBJECTIVES: To determine wheth …
Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.
Leri F, Burns LH. Leri F, et al. Pharmacol Biochem Behav. 2005 Oct;82(2):252-62. doi: 10.1016/j.pbb.2005.08.008. Epub 2005 Sep 21. Pharmacol Biochem Behav. 2005. PMID: 16182352
Our present studies in male Sprague-Dawley rats assessed the abuse potential of oxycodone+ultra-low-dose naltrexone (NTX) versus oxycodone alone. The lowest NTX dose (1 pg/kg/infusion), but not slightly higher doses (10 and 100 pg/kg/infusion), enhance …
Our present studies in male Sprague-Dawley rats assessed the abuse potential of oxycodone+ultra-low-dose naltrexone
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
Tompkins DA, Lanier RK, Harrison JA, Strain EC, Bigelow GE. Tompkins DA, et al. Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13. Psychopharmacology (Berl). 2010. PMID: 20386884 Free PMC article. Clinical Trial.
OBJECTIVE: Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX) may have increased analgesic potency and have suggested reduced abuse or dependence liability. This study addressed whether addition of …
OBJECTIVE: Preclinical and clinical studies have shown that opioids combined with ultra-low-dose naltrexone (NTX …
Ultra-low dose naltrexone potentiates the anticonvulsant effect of low dose morphine on clonic seizures.
Honar H, Riazi K, Homayoun H, Sadeghipour H, Rashidi N, Ebrahimkhani MR, Mirazi N, Dehpour AR. Honar H, et al. Neuroscience. 2004;129(3):733-42. doi: 10.1016/j.neuroscience.2004.08.029. Neuroscience. 2004. PMID: 15541894
Moreover, inhibition of opioid-induced excitatory signaling by naltrexone (1 ng/kg) unmasked a strong anticonvulsant effect for very low doses of morphine (1 ng/kg-100 microg/kg), suggesting that a presumed inhibitory component of opioid receptor signaling can exert strong seizur …
Moreover, inhibition of opioid-induced excitatory signaling by naltrexone (1 ng/kg) unmasked a strong anticonvulsant effect for very low dos …
21 results